MARATTO

article · International Journal of Biochemistry Research & Review

Human Tumor Necrosis Factor-α as a Diagnostic Marker for Chronic Diabetic Nephropathy

20241 citationOpen accessBadr University in Cairo

Abstract

Background: diabetic nephropathy (DN) is a chronic main microvascular consequence of untreated hyperglycemia, affects a significant portion of the population. It's thought to be the main factor causing end-stage kidney disease. TNF-α is involved in the development and course of disease in DN. Aim: This study aimed to evaluate plasma TNF-α as a new diagnostic marker for early DN. Patients and Methods: This study included 125 Egyptian subjects attending the out Patients Clinic of the Department of Internal Medicine, 10Th of Ramadan city Health Insurance Hospital and divided as follow:- Control group , Study groups( patient with diabetic mellitus (DM),DN, DN and other complications). Control& study group were subjected to measurement of glycosylated hemoglobin (HbA1C), creatinine, total cholesterol, triglycerides, F.B.G, GFR ,HDL, LDL, ALT, AST, total protein, albumin, globulin, A/G ratio, HDL, LDL, ACR,TNF-α. Results: results showed that plasma TNF-α was positive and significantly correlated with BMI, duration of DM, F.B.G, HbAIC, CR, GFR, CHOL, HDL, LDL, AST, A/G ratio, Meanwhile, plasma TNF-α was negatively correlated with ACR, TG, ALT, ALB, TP and GLB. At cut-off level ≥83.5, TNF-α had 96.7% sensitivity and 79.7% specificity for diagnosing diabetic nephropathy. Conclusion: The study found that patients in study group had considerably higher plasma levels of TNF-α. This suggests that TNF-α May be used as a markers for predicting chronic DN in patients with type 2 diabetes.

Research topics

  • Biomarkers in Disease Mechanisms
  • Chronic Kidney Disease and Diabetes
  • Liver Disease Diagnosis and Treatment

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.9734/ijbcrr/2024/v33i6933

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.